Connie S. Zhang
Research Subjects
Connie S. Zhang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Amber L. Simpson
School of Computing, Queen’s University, Kingston, Canada
12 shared publications - Ami Wang
Department of Pathology and Molecular Medicine Kingston Health Sciences Centre and Queen's University Kingston Ontario Canada
12 shared publications - Andrew Garven
Department of Biomedical and Molecular Sciences, Queens University, Kingston, Ontario, Canada
12 shared publications - Andrew W. B. Craig
Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada
12 shared publications - Brian J. Laight
Dept Pathology and Molecular Medicine, School of Medicine, Queen's University, Kingston, ON, Canada; Division of Cancer Biology and Genetics, Sinclair Cancer Research Institute, Queen's University, Kingston, ON, Canada
12 shared publications - Caitlyn Vlasschaert
Department of Medicine, Queen’s University, Kingston, Ontario, Canada
12 shared publications
Latest Publications
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
UK Biobank FES rs17514846 SNP analysis
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
UK Biobank FES rs17514846 SNP analysis
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Extended Data Figure 6 from Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Fes-deficiency increases sensitivity to LPS stimulation.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessExtended Data Figure 6 from Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Fes-deficiency increases sensitivity to LPS stimulation.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Extended Data Figure 1 from Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Tumor growth rates and survival advantages to lower FES expression or mutational status.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessExtended Data Figure 1 from Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Tumor growth rates and survival advantages to lower FES expression or mutational status.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Extended Data Figure 9 from Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Fes-deficiency improves T cell priming capabilities of BMDMs at a range of SIINFEKL concentrations in a Signal 2-independent mechanism.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessExtended Data Figure 9 from Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Fes-deficiency improves T cell priming capabilities of BMDMs at a range of SIINFEKL concentrations in a Signal 2-independent mechanism.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Extended Data Figure 3 from Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Fes is expressed in bone marrow derived macrophages, B cells, and NK cells, but not T cells.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessExtended Data Figure 3 from Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Fes is expressed in bone marrow derived macrophages, B cells, and NK cells, but not T cells.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Immune profiling antibody panels
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Immune profiling antibody panels
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Extended Data Figure 5 from Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
PD-1 therapy delays tumor growth rates only in Fes-/- mice.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessExtended Data Figure 5 from Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
PD-1 therapy delays tumor growth rates only in Fes-/- mice.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Extended Data Figure 8 from Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Fes-deficient BMDMs show time-dependent changes in cytokine expression and localization.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessExtended Data Figure 8 from Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Fes-deficient BMDMs show time-dependent changes in cytokine expression and localization.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Extended Data Figure 7 from Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Fes-deficiency confers increased cytokine expression.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessExtended Data Figure 7 from Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Fes-deficiency confers increased cytokine expression.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Extended Data Figure 2 from Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Representative IHC and immunoblot staining of premalignant murine mammary glands.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessExtended Data Figure 2 from Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Representative IHC and immunoblot staining of premalignant murine mammary glands.